Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.63 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | TACR1 | P25103 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139390 | 0.88 | CTSK (0.66) | CTSLCTSBCTSSCTSK | |
| SCHEMBL8823902 | 0.84 | CTSK (0.68) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7314524 | 0.84 | CTSL (0.73) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL9557048 | 0.84 | CTSL (0.73) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7360694 | 0.84 | CTSS (0.63) | CTSLCTSBCTSSCTSKHDAC8 | |
| SCHEMBL8335400 | 0.83 | CTSL (0.71) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL8823896 | 0.83 | CTSK (0.66) | CTSLCTSBCTSSCTSK | |
| SCHEMBL10521480 | 0.82 | CTSL (0.70) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL31207208 | 0.82 | CTSL (0.70) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL5934832 | 0.82 | CTSK (0.70) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSL 14/4885CTSB 11/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.